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A mis-sense point mutation in the human VAPB gene is associated with a familial form of motor neuron
disease that has been classified as Amyotrophic Lateral Sclerosis type VIII. Affected individuals suffer
from a spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) or an atypical slowly progressing
form of ALS. Mammals have two homologous VAP genes, vapA and vapB. VAPA and VAPB share 76% similar
or identical amino acid residues; both are COOH-terminally anchored membrane proteins enriched on the
endoplasmic reticulum. Several functions have been ascribed to VAP proteins including membrane traffick-
ing, cytoskeleton association and membrane docking interactions for cytoplasmic factors. It is shown here
that VAPA and VAPB are expressed in tissues throughout the body but at different levels, and that they
are present in overlapping but distinct regions of the endoplasmic reticulum. The disease-associated
mutation in VAPB, VAPBP56S, lies within a highly conserved N-terminal region of the protein that shares
extensive structural homology with the major sperm protein (MSP) from nematodes. The MSP domain of
VAPA and VAPB is found to interact with the ER-localized transcription factor ATF6. Over expression of
VAPB or VAPBP56S attenuates the activity of ATF6-regulated transcription and the mutant protein
VAPBP56S appears to be a more potent inhibitor of ATF6 activity. These data indicate that VAP proteins inter-
act directly with components of ER homeostatic and stress signalling systems and may therefore be parts of
a previously unidentified regulatory pathway. The mis-function of such regulatory systems may contribute to
the pathological mechanisms of degenerative motor neuron disease.
INTRODUCTION
A dominantly inherited familial form of motor neuron disease
characterized in a large Brazilian family was recently shown
to be associated with a mis-sense mutation in the human
vapB gene (1). Affected individuals suffer from three different
pathological conditions; a late on-set slowly progressing spinal
muscular atrophy (SMA), a slowly progressing late on-set
atypical amyotrophic lateral sclerosis ALS8 or a typical
severe rapidly progressing ALS (2,3). Although familial forms
of disease may represent less than 5% of the total incidences
of ALS (4,5), they exhibit the same phenotypic heterogeneity
as the more common sporadic disease (6–8). Information on
the mechanistic basis of familial motor neuron diseases may,
therefore, be relevant to all forms of motor neuron disease.
The first VAP protein was identified in Aplysia californica
from its interaction in a yeast two-hybrid screen with
VAMP/Synaptobrevin, hence the nomenclature VAMP/
Synaptobrevin Associated Protein (9). VAP proteins are
highly conserved, with homologous proteins found in all
eukaryotes (10–15). There are two mammalian genes VapA
and VapB (16). The proteins contain three prominent structural
features; the N-terminal domain of approximately 120 amino
acids is highly homologous to the nematode major sperm
protein (MSP) (17), the central domain is amphipathic and
predicted to form a coiled–coil structure, and the C-terminal
20 amino acids are hydrophobic and act as an intracellular
membrane anchor (13,15,16).
The MSP domain binds to the ‘two phenylalanines in an
acid tract’, or ‘FFAT’ motif found in several cytoplasmic
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lipid-binding proteins (18–20). The structural basis of this
interaction was recently determined for the MSP domain of
VAPA (21). Thus, VAP proteins may act as docking sites
for cytoplasmic factors to interact with the ER. VAP proteins
may also act to maintain the structure of intracellular mem-
branes such as the ER, by interacting with the cytoskeleton
and mediating membrane trafficking (13,15,22).
The disease-associated mutation in ALS8 is a C to T substi-
tution within exon 2 of the vapB gene replacing a proline
residue with a serine in a highly conserved region of the
protein. The mutant protein, VAPBP56S, forms aggregates
when expressed in cultured cell lines or primary hippocampal
neurons (1). The relationship of these aggregates to the patho-
logical mechanism of the disease is not known. It has been
suggested that the presence of aggregates containing
VAPBP56S may result in disruption of the proteasome, acti-
vation of ER stress responses, fragmentation of the Golgi
apparatus and induction of apoptosis (23). Teuling et al. (24)
have also demonstrated that expression of VAPBP56S recruits
the wild-type protein into aggregates and causes disruption
of ER structure.
In this report, we show that both VAPA and VAPB are ubi-
quitously expressed but at differing levels in different tissues
and that they accumulate on overlapping but distinct regions
of the ER. Both VAPA and VAPB are shown to be capable
of interacting with the ER stress regulated transcription
factor ATF6, and over expression of VAPB or VAPBP56S
attenuates the activity of an ATF6/XBP1 regulated promoter.
This suggests that VAPB can have an inhibitory effect on
ATF6 dependent transcription and that the disease-associated
mutant, VAPBP56S, has an enhanced inhibitory activity
towards ATF6-dependent transcription compared to the wild-
type protein. An interaction between VAP proteins and
ATF6 may represent a previously uncharacterized mechanism
of ER homeostatic and stress response regulation.
It is concluded that the mis-regulation of ER stress response
and homeostatic regulatory systems may contribute to the
pathological mechanism of degenerative motor neuron
disease associated with the VAPBP56S mutation.
RESULTS
VAPA and VAPB are expressed ubiquitously but at
differing levels in different tissues
Immunoblot analysis of selected tissues from an adult male rat
demonstrated that both VAPA and VAPB proteins are present
in all tissues examined, but at different relative levels
(Fig. 1A). This is in agreement with the wide expression
profile of mRNA published previously (13,16,25). A second
protein of slightly larger molecular weight is detected in the
testis by VAPA anti-sera. An additional, less abundant,
protein of approximately 14 kDa is detected by both anti-
serum. The VAPB-related signal is a doublet, the expression
of which is tightly restricted to the forebrain and cerebellum
extracts, and not detected in the other tissues tested
(Fig. 1A). The 14 kDa VAPA-related polypeptide is more
widely expressed and detectable in pancreas, liver, forebrain,
lung and thymus, kidney and testis; low levels are seen in
the cerebellum and no signal is detected in heart or skeletal
muscle. A peptide of similar size has been predicted from a
splice variant of VAPB, termed VAPC. However, the
peptide used to generate the VAPB anti-serum is not present
in VAPC (16), and the VAPA anti-sera do not cross react sig-
nificantly with vapB-derived species (Supplementary Material,
Figure S1). It is concluded that these smaller molecular weight
immunoreactive species are most likely generated by proteol-
ysis of the VAP proteins.
It has been shown previously that both VAPA and VAPB
are enriched on the ER membrane (13,15,21). A distinct sub-
cellular distribution for the two proteins is seen by
co-immunostaining of HEK293 cells (Fig. 1B). Both proteins
are localized in a reticular pattern, but they exhibit only a
modest level of co-localization. This distinct sub-cellular dis-
tribution of VAPA and VAPB is most striking in skeletal
muscle (Fig. 1C). Fluorescent immunocytochemistry indicates
a complementary distribution of VAPA and VAPB in the sar-
coplasmic reticulum. VAPA is enriched on the A- and
H-bands and the Z-line, while VAPB is restricted to the
I-band and T-system regions (Fig. 1C). The I-band is enriched
for IP3 receptors and RyR localize mainly at the T-system
(26); VAPA and VAPB may therefore be associated with dis-
tinct intracellular calcium stores.
Interactions of the VAP MSP domain
The ALS8-associated mutation in the VAPB protein lies
within a highly conserved region of the MSP domain. In a pre-
vious series of experiments, we had observed that, when
expressed as an EGFP fusion protein, the MSP domains of
both VAPA and VAPB formed intensely fluorescent, large
intracellular aggregates and were toxic to HEK293 and
PC12 cell lines, and to primary cultures of rodent hippocampal
neurons (Skehel, unpublished). To investigate possible mech-
anisms of the MSP domain toxicity, a yeast two-hybrid screen
was done to identify potential MSP interacting proteins. A
sequence corresponding to amino acids 1–107 of mouse
VAPA was used to screen a rat brain cDNA library. In
addition to a number of FFAT- and MSP domain-containing
proteins, a partial clone of the ER stress regulated transcription
factor ATF6 was identified (27).
To characterize this interaction further, expression con-
structs for full-length VAPA, VAPB and ATF6 were analysed
by a fluorescent peptide complementation assay (28) (Fig. 2).
In this assay, a fluorescent protein is generated from two sep-
arate parts of a split GFP, termed Venus1 and Venus2, only by
the association of two test polypeptides expressed as fusion
proteins. A functional fluorescent protein is generated when
the two test proteins directly interact. Although the initial
yeast two-hybrid interaction was between a truncated form
of ATF6 and the MSP domain of VAPA, an interaction
between full-length forms of VAPA and VAPB with ATF6
was readily detectable (Fig. 2). Similarly, the ALS8-associated
mutant VAPBP56S was shown to be capable of interacting with
ATF6 (Fig. 2). No interaction was detected between VAPA,
VAPB or ATF6 when co-expressed with heterologous
leucine zipper-Venus fusions. The reconstitution of a fluor-
escent protein clearly indicates that VAPA and VAPB are
capable of interacting with ATF6. Similar results were also
obtained with the converse Venus combinations, where
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ATF6 was expressed as a fusion with Venus 1, and the VAP
proteins were fused to Venus 2 (data not shown) (28).
Fluorescence analysis of HEK293 cells expressing EGFP-
VAPB and FLAG-tagged ATF6 shows extensive regions of
co-localization on the ER, but also some complementary
distribution (Fig. 3). The aggregates of EGFP-VAPBP56S
show some but not extensive co-localization with ATF6,
although we cannot discount that low antigen accessibility
may contribute to reduced ATF6 detection in VAPBP56S
aggregates. Expression of VAPBP56S does not appear to
cause gross disruption of ATF6 distribution in the ER (Fig. 3).
ATF6 is inhibited by VAPB and VAPBP56S
ATF6 is one of a family of transmembrane transcription
factors (29). It functions in a regulated transcription pathway
Figure 1. (A) Detection of VAPA and VAPB in different tissues. Anti-peptide anti-serum was raised to residues 174–189 of mouse VAPB. In the tissues indi-
cated, the predominant immunoreactivity is at approximately 27 kDa, in agreement with the molecular weight predicted from the cDNA. Both VAPA and VAPB
are expressed widely but at different levels. A faster migrating VAPB-related doublet signal of approximately 14 kDa is clearly detected in forebrain and
cerebellum protein extracts (arrows). The immunoblot is deliberately over exposed to demonstrate the restricted nature of this expression pattern. A faster
migrating immunoreactive species of approximately 14 kDa is also seen with VAPA anti-sera, however, in contrast to that seen for VAPB; this species is detect-
able in pancreas, liver, forebrain, lung and thymus, kidney and testis; low levels are seen in the cerebellum and no signal is detected in Heart or skeletal muscle.
(B) VAPA and VAPB are expressed in distinct reticular patterns. Indirect immunoflouroescence analysis of VAPA and VAPB in HEK293 cells reveals a reticular
pattern of expression, but detects very little co-localization of the two proteins. VAPA is shown in red and VAPB in green. (C) VAPA and VAPB are enriched in
a complementary distribution in skeletal muscle. Confocal micrographs of an immunocytochemically labelled transversus abdominis muscle from a 2 month old
mouse (VAPA in red, VAPB in green). The staining patterns of VAPB were consistent with it being located around putative I—band and T-system regions. In
contrast, VAPA was absent from these regions, and appeared to be more strongly expressed in the regions associated with A- and H-bands and Z-lines. A pseudo-
coloured electron micrograph is shown to indicate the position of VAPA and VAPB staining in relation to the structure of a muscle sarcomere.
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involved in ER homeostasis and response to stress known as
the unfolded protein response (UPR) (30–32). Upon accumu-
lation of unfolded proteins in the lumen of the ER, ATF6
translocates from the ER to the Golgi and is proteolyzed in
turn by S1P and S2P. This results in the release of the DNA
binding and transcription transactivation domain of ATF6
from the ER membrane allowing it to enter the nucleus and
activate transcription (27,33).
ATF6 appears to interact with several promoter elements
(31,34,35). A synthetic promoter has been generated that acts
as an ATF6/XBP1 dependent transcription reporter (31). To
determine if the interaction with VAPB affects the ability of
ATF6 to activate transcription, luciferase-based transient trans-
cription assays were done using this ATF6/XBP1-dependent
reporter of transcription (31). In HEK293 cells, basal levels
of transcription from this promoter are reduced by over-
expression of myc-tagged forms of VAPB or VAPBP56S
(Fig. 4A). ATF6/XBP1-mediated transcription activated by
the glycosylation inhibitor, tunicamycin, was also significantly
reduced by over expression of VAPB or VAP-BP56S (Fig. 4A)
(36,37). Increasing levels of ATF6 by co-expression of a
FLAG-tagged recombinant form of human ATF6 (38) increased
basal and tunicamycin-induced expression from the ATF6/
XBP1 reporter. In both cases, the elevated levels of ATF6/
XBP1 dependent transcription were also reduced by over
expression of either VAPB or VAPBP56S (Fig. 4B). This
effect requires the cytoplasmic domains of VAPB and does
not appear to be a non-specific consequence of increasing
levels of protein in the ER membrane since over expression
of a DsRed fluorescent fusion protein of the C-terminal
Figure 2. Peptide complementation assay for the interaction of VAPA and VAPB with ATF6. The coding sequences of mouse VAPA, VAPB and VAPBP56S
were expressed in HEK293 cells as fusion proteins with a truncated non-fluorescent form of YFP, Venus 1 (28). These proteins were co-expressed with the
complementary ATF6-Venus 2 fusion protein. Fluorescence indicates reconstitution of a functional YFP and therefore a direct interaction of VAPA and
VAPB with ATF6. Wild-type VAPB and mutant VAPBP56S are capable of interacting with ATF6. Controls in which a homodimerizing leucine zipper
peptide was expressed as either a Venus 1 or Venus 2 fusion proteins show no fluorescence when expressed with the complementary VAP or ATF6 fusion pro-
teins. Bright field or fluorescence images were acquired from live cells through cell culture plastic.
Figure 3. Co-localization of VAPB and ATF6. HEK293 cells were transfected
with FLAG-ATF6, EGFP-VAPB and EGFP-VAPBP56S. In colour plates,
FLAG-ATF6 is shown in red and EGFP-VAPB or EGFP-VAPBP56S is in
green. There is extensive, but not total co-localization of VAPB and ATF6
in a reticular distribution. ATF6 co-localizes with the aggregates formed by
VAPBP56S, but not in a punctate pattern. Note that VAPBP56S does not
cause a gross change in the distribution of ATF6.
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hydrophobic domain of VAPB does not reduce the basal or
tunicamycin-induced expression from the ATF6/XBP1 reporter
(Fig. 4A and Supplementary Material, Figure S3). Over
expression of VAP proteins does not reduce expression levels
of luciferase directed from a CMV promoter; therefore, the
repressive affect on the ATF6/XBP1 reporter is unlikely to be
the result of a general repression of transcription (Supplemen-
tary Material, Figure S4).
A similar inhibitory affect was also seen in the motor
neuron derived cell line NSC34 (Fig. 4C and D). In NSC34
cells, basal levels of expression from the ATF6/XBP1 reporter
are less than in HEK293, perhaps indicating lower levels of
endogenous ATF6.
Consistent with the inhibitory affect seen by over
expression of VAPB, siRNA-mediated reduction of endogen-
ous VAPB results in an increase of basal and induced levels
of ATF6/XBP1-dependent transcription (Fig. 5).
When equal amounts of expression plasmid DNA for VAPB
and VAPBP56S were used for cell-transfections, the overall
level of attenuation was similar between the wild type and
mutant forms of VAPB (Fig. 4). Immunoblot analysis of
total protein from transfected cells, however, indicated that
the mutant protein, VAPBP56S-myc, accumulated to signifi-
cantly lower levels, reaching only 20% of the level of wild-
type protein (Fig. 6). This suggests that VAPBP56S-myc may
exert a stronger inhibition on ATF6 than the wild-type
VAPB-myc, since a similar level of inhibition is achieved
from a lower amount of protein. The difference in protein
levels is less pronounced when VAPB and VAPBP56S are
expressed as EGFP fusion proteins (Fig. 6), which indicates
that the presence of the GFP moiety may have a stabilizing
affect on VAP-BP56S. Consistent with this, the inhibition
of ATF6/XBP1-dependent transcription is more pronounced
for VAPBP56S-GFP than VAPB-GFP (Fig. 6). Thus,
VAPBP56S appears to have a significantly greater inhibitory
affect on ATF6 mediated transcription than wild-type
VAPB. These results suggest that mis-regulation of ER
stress responses may be important for the pathological effect
of VAPBP56S that leads to motor neuron degeneration.
DISCUSSION
The identification of a mutated gene responsible for a familial
form of motor neuron disease greatly facilitates molecular and
cellular studies of potential disease mechanisms. Understand-
ing the cellular function of VAPB may indicate what molecu-
lar and cellular events are associated with the disease process
of ALS8. It is likely that this information will be of relevance
to both the inherited condition and the more common sporadic
forms of disease.
Previous studies have demonstrated a role for VAP proteins
on the ER. The N-terminal MSP domain contains an FFAT-
motif binding site (21). This interaction has been shown to
localize a number of cytoplasmic lipid-binding proteins to
the ER and ER-derived membranes (18–20,39). FFAT-
dependent interactions between VAPA and Nir2 and 3 have
also been shown to affect the gross structure of the ER (22).
Both VAPA and VAPB appear to be expressed at different
relative levels in specific tissues [(16,25) and this study].
Figure 4. VAPB and VAPBP56S inhibit transcription from an ATF6 regulated transcription reporter. (A) HEK293 were transfected with a reporter plasmid con-
taining the luciferase cDNA regulated by five ATF6/XBP1 binding sites, pGL3(5X)ATF6. Cell cultures were co-transfected with expression plasmids encoding
VAPB or VAPBP56S as myc-tagged fusion proteins (VAPB-myc and VAPBP56S-myc) or a monomeric red fluorescent fusion protein containing the C-terminal 41
amino acids of VAPB (VAPB-Cterm). Where indicated cultures were treated for 12 h with 2 mg/ml Tunicamycin to induce ER stress. VAPB and VAPBP56S
reduce constitutive levels of ATF6/XBP1 activity, while VAPB-Cterm had no effect. (B) Over expression of ATF6 as a ATF6-FLAG fusion protein increased
basal and tunicamycin-induced activity of the ATF6/XBP1 reporter gene, but in both cases, levels of activity were reduced by co-expression of VAPB-myc or
VAPBP56S-myc. (C and D) The same experiments using the motor neuron-like cell line NSC34 gave similar results.
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Both proteins are enriched on the ER and co-localize to a large
extent (24). There are, however, many regions where the two
proteins do not co-localize, suggesting they are present in dis-
tinct functional regions of the ER. This is most clearly seen in
skeletal muscle where VAPA is enriched within the A and H
bands and Z-line, whereas VAPB is seen predominantly in the
I-bands and T-region. The localization of VAPA is similar to
that of the IP3 receptor (26), whereas VAPB more closely
resembles the distribution of Ryanodine receptors (40). Any
disruption of VAPB function caused by the P56S mutation
associated with ALS8 might, therefore, affect intracellular
Ca2þ storage and Ca2þ signalling capacities. Intracellular
Ca2þ levels have been implicated in many degenerative con-
ditions (reviewed in 41), and inhibition of Ryanodine receptor
activity has been recently suggested as a possible pathological
mechanism for motor neuron disease (42).
The proline residue at codon 56 within the MSP domain
does not appear to contribute directly to FFAT-binding but
co-immunoprecipitation of FFAT-containing proteins is
reduced for VAPBP56S (24). Perturbation of FFAT-dependent
association with the ER could disrupt the sorting of lipids
within and between cellular membranes (19,20). A
phosphoinositide-binding activity has been identified in the
MSP domain of the yeast protein SCS2 that is a homologue
of VAPA and VAPB (43).
Disruption of the MSP domain in VAPBP56S could affect a
similar activity in the mammalian proteins. Changes in mem-
brane composition have been suggested as a cause of neurode-
generation (44), and hyperlipidaemia is one of the clinical
effects reported for VAPBP56S families (3). Disruption of ER
and Golgi structure and/or function has been suggested pre-
viously as a possible pathological mechanism for degenerative
diseases of neurons (45–47). More recently, ER stress in par-
ticular has been associated with sporadic and experimental
models of motor neuron disease (48–50), and neurodegenera-
tion in general (reviewed in 46,47,51). A recent report has also
suggested that VAPB levels may induce the ER UPR by
affecting the activity of IRE1 (23). In this report, we show
that VAPA and VAPB can interact directly with the
ER-localized transcription factor ATF6. Moreover, increasing
the expression of VAPB attenuates the activity of ATF6,
whereas reducing VAPB levels enhance ATF6-dependent
transcription. Over expression of the mutant protein
VAPBP56S appears to attenuate the activity of ATF6 more pro-
foundly than does wild-type VAPB. The pertinacious aggre-
gates formed by VAPBP56S do not appear to sequester ATF6
to a significant extent. The enhanced inhibitory affect of
VAPBP56S levels on ATF6 activity may not, therefore, be
due simply to a reduction in available ATF6. There are a
number of stages in the activation of ATF6 that VAPB
could influence. In response to accumulation of unfolded
protein in the ER lumen ATF6 translocates from the ER to
the Golgi. There it is sequentially processed by S1P and S2P
proteases to release an amino terminal portion of the protein
containing DNA binding and trans-activation domains (33).
The lumental COOH-terminal domain of ATF6 is required
to detect the accumulation of unfolded proteins in the lumen
of the ER. As VAPB has very little luminal structure, it is unli-
kely to directly inhibit the ability of ATF6 to detect ER stress.
Over expression of VAPB can disrupt membrane trafficking
and so may indirectly inhibit the activation of ATF6 by redu-
cing the translocation of ATF6 to the Golgi (15). Alterna-
tively, VAP proteins might directly inhibit the translocation
of ATF6 to the Golgi. It is also possible that VAP acts after
translocation of ATF6 to the Golgi by a mechanism similar
to that of Nucleobindin1 which represses S1P activation of
ATF6 (52).
VAPB may act at the level of transcription. The yeast VAP
homologue SCS2, originally identified as a suppressor of ino-
sitol auxotrophy, has been shown to localize activated genes to
the nuclear membrane via an interaction with a FFAT domain-
containing protein, Opi1 (10,53). The localization to the
nuclear membrane was essential for gene expression (53). If
an analogous situation existed in mammals, over expression
of VAPB could directly affect the activity of ATF6 at promo-
ters adjacent to the nuclear membrane.
Figure 5. VAPB siRNA reduces the levels of endogenous VAPB and increases basal ATF6/XBP1-dependent transcription. (A) Immunoblot analysis of HEK293
cells nucleofected with VAPB siRNA or GFP siRNA and non-transfected cells shows a 25% reduction in levels of endogenous VAPB when treated with VAPB
siRNA and no reduction in GFP siRNA treated cells. A 60 kDa non-specific band from longer exposures of the immunoblot serves as a loading control. Band
intensities were measured using ImageJ (NIH). (B) siRNA to VAPB increases basal and tunicamycin-induced, transcription from an ATF6/XBP1-regulated tran-
scription promoter.
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A regulatory role for VAP proteins on the surface
of the ER
The UPR and ERAD systems respond to the environment of
the lumen of the ER. Perhaps the interaction between the
VAP proteins and ATF6 represents an additional element of
ER regulation that responds to levels of proteins associating
with the surface of the ER, or to proteins that do not have sig-
nificant amounts of luminal structure.
VAP proteins interact with a broad range of other coiled–
coil containing proteins such as VAMP/Synaptobrevin and
syntaxin (12). If interactions of the coiled/coil domain also
affected the MSP domain-dependent inhibition of ATF6,
they could enable the levels of membrane proteins on the
surface of the ER to activate ATF6.
VAP proteins and Hepatitis C virus replication
The Hepatitis C virus has exploited potential structural and
regulatory functions of the VAP proteins. Hepatitis C repli-
cates in association with the ER. Two of the viral proteins
required for this association, NS5A and NS5B, can bind to
both VAPA and B, interacting with the coiled–coil and
MSP domains, respectively (54,55). Disrupting these inter-
actions or down-regulating VAPA and VAPB protein levels
inhibits virus replication (55,56). Hepatitis C protein
expression can also induce ER stress, activating both ATF6
and XBP1. This does not lead to a full UPR (57,58), and it
has been suggested that mis-regulation of the ER stress
response may in someway favour viral replication (58).
Perhaps a similar mechanism may contribute to the pathogen-
esis of VAPBP56S. The mutant protein could lead to a mis-
regulation of ER stress regulatory pathways via aberrant
ATF6 activity. Such mis-regulation could also have a role in
the pathological affects of Hepatitis C infection.
ATF6 activity and neurodegeneration
The increased level of ATF6 inhibition by VAPP56S suggests
that a possible pathological mechanism for ALS8 is
mis-function of homeostatic regulatory systems of the ER.
Kanekura et al. (23) recently demonstrated that increased
VAPB levels could induce the UPR as indicated by activation
of XBP1, and that the affect of VAPBP56S was to diminish this
activation. Our study suggests that VAP proteins can also
affect the activity of ATF6, and that the mutation VAPBP56S
may, have a greater effect than the wild-type protein VAPB.
From gene transcription analysis on the UPR in C. elegans,
it has been shown that ATF6 mainly contributes to tonic
levels of gene expression (59). In mammals, ATF6 appears
to have a more extensive role in the ER stress response,
where it is required for the induced expression of principal
ER chaperones, and also acts as a heterodimer with XBP1 to
induce components of the ER associated degradation
pathway (ERAD) (30).
The direct interaction between VAP proteins and ATF6
represents a previously uncharacterized mechanism for the
Figure 6. VAPBP56S accumulates to lower levels than VAPB. Immunoblot analysis of HEK293 cells expressing myc or GFP-tagged forms of VAPB and
VAPBP56S. Duplicate samples are shown, and relative levels expressed as a histogram of signal intensities. As both myc and GFP fusion proteins,
VAPBP56S accumulates to lower levels than VAPB. VAPBP56S-myc is 15% the level of VAPB-myc, and VAPBP56S-GFP is 50% the level of
VAPB-GFP. (A) The GFP moiety appears to have a stabilizing affect on the levels of mutant protein, allowing it to accumulate to higher levels than the myc-
tagged form. (B) Consistent with this the inhibition of ATF6-dependent reporter gene expression is reduced to a greater relative level by VAPBP56S-GFP than
VAPBP56S-myc. Band intensities were determined using ImageJ (NIH) Intensities for both myc and GFP, VAPB and VAPBP56S were normalized to the p38
loading control.
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regulation of transcriptional responses made to changes in ER
metabolism. Overall, VAP proteins may have structural and
regulatory functions based on interactions of the MSP
domain. The pathological mechanism in ALS8, therefore,
may be the result of an inability to deal appropriately with
different forms of ER stress.
MATERIALS AND METHODS
Antisera. VAPB-specific anti-serum was raised in sheep to a
multi antigenic peptide (MAP) form of a peptide correspond-
ing to amino acids 174–189 of mouse VAPB (Alta Bio-
science). This sequence is identical in rats and mice. The
serum was affinity purified using the immunizing peptide.
The VAPA anti-serum has been described previously (13).
Anti-myc was monoclonal 9E10 and anti-FLAG was M2
(Sigma).
Muscle staining
Muscle tissue was fixed in 0.1 M PBS containing 4% parafor-
maldehyde for 1–2 h.
Muscles were blocked in 4% BSA and 0.5% Triton-X (both
Sigma) in PBS for 30 min before incubation in primary anti-
bodies overnight at 48C. The primary antibodies used were
sheep anti-VAPB (1:200) and rabbit anti-VAPA (1:300).
After washing for 30 min in blocking solution, muscles were
incubated for 4–5 h in PBS containing secondary antibodies.
The secondary antibodies used were Donkey anti-Sheep Cy2
(1:100, Jackson Laboratories) and Donkey anti-Rabbit Cy3
(1:100, Jackson Laboratories). After a 2 h wash in PBS,
muscles were mounted on glass slides in mowoil mounting
medium [2.4 g mowoil (Poly vinyl Alcohol, Calbiochem),
6 g glycerol, 2.5% 1,4-diazobicyclo-octane (DABCO,
antifade, Sigma), 12 ml 200 mM Tris (pH 8.5)). These exper-
iments are not shown.
Preparations were analysed using a laser confocal scanning
microscope (Biorad Radiance 2000). The strobing function
was always enabled to prevent signal bleeding through from
one channel to another. Confocal z-series were merged using
Lasersharp (Biorad) software. All images were analysed and
prepared for presentation in Adobe Photoshop.
Cell staining
HEK293 cells grown on poly-D-lysine coated cover slips were
fixed in 3% paraformaldehyde, 0.03% glutaraldehyde (w/v) in
PBS, at room temperature for 20 min. Fixative was quenched
and cells permeablized with a solution of 50 mM NH4Cl, 0.2%
(w/v) Saponin (Sigma), for 15 min at room temperature. Cells
were washed, and antibodies diluted in a solution containing
0.2% (w/v) fish skin gelatin (Sigma G-7765), 0.02%
saponin, in PBS. Inverted cover slips were mounted in
Mowoil, and examined on a Zeiss Imager.Z1 microscope
fitted with a LSM 510 Meta confocal excitation/acquisition
system.
Peptide complementation
Full-length coding sequences for mouse VAPA, VAPB,
VAPAP56S, VAPBP56S and human ATF6a (NM_007348)
were amplified in a PCR that introduced flanking BspEI and
XbaI, or NotI and ClaI restriction sites, and sub-cloned into
pcDNA3.1(zeo)-Venus[1] or pcDNA3.1(zeo)-Venus[2],
respectively (28). HEK293 were transfected using Lipofecta-
mine 2000 (Invitrogen). For each transfection 200 ng of total
DNA was used. Images of living cells were acquired 24 h
after transfection on an Olympus IX70 fluorescence micro-
scope using Openlab software (Improvision). Representative
images are shown.
Transcription assay
HEK293 or NSC-34 cells were grown in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% foetal bovine serum.
Cells were transfected using Lipofectamine2000 (Invitrogen).
Each transfection mixture contained 300 ng of p5xATF6-GL3
(31) and 100 ng of the internal control renilla luciferase repor-
ter, pTK-RT. VAPB and VAPBP56S were expressed as EGFP-
fusion proteins derived from pEGFP-C1 (Clontech), or as myc
epitope tagged fusion proteins where the EGFP coding
sequence was replaced with a myc epitope coding sequence.
The total amount of DNA per transfection was 500 ng.
ATF6 was over expressed as a FLAG-tagged fusion protein
from pCMV-ATF6-3xFLAG7.1 (60). One hundred nanogram
of each VAPB and ATF6 expression plasmid was used, with
the total amount of DNA in each transfection made up to
600 ng with the vector pEGFP-C3 (Clontech). Twenty-four
hours after transfection ER stress was induced for 12 h with
2 mg/ml tunicamycin (Calbiochem). Cells were then lysed
and assayed for firefly and renilla luciferase activity using
the Dual GloTM Luciferase Assay System (Promega). Firefly
and renilla luminescence were measured using a FLUOstar
OPTIMA micro-plate reader (BMG LABTECH). Firefly luci-
ferase luminescence values are normalized to renilla firefly
luminescence values and are averages of four experiments
with SE.
siRNA transfection
106 HEK293 cells were nucleofected with 200 pMoles of
VAPB siRNA (Quiagen) or a control GFP-siRNA (Dharma-
con) using the Amaxa Biosystems nucleofector. Twenty-four
hours after nuclofection, cells were transfected with
p5xATF6-GL3 and pTK-RT as described above. After a
further 24 h, cells were treated with 2 mg/ml Tunicamycin
(Calbiochem) for 12 h and then assayed for luciferase activity
as above.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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